DR info

臨床試験数 : 8 / 薬物数 : 7 - (DrugBank : 3) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 1

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Cyclophosphamide
   Royal Brompton & Harefield NHS Foundation Trust
      2014   Phase 2/Phase 3   NCT01862926   United Kingdom;
Cyclophosphamide Injection 1g
   Royal Brompton and Harefield NHS Foundation Trust
      2013   -   EUCTR2012-003633-42-GB   United Kingdom;
MHV370
   Novartis Farmacéutica, S.A.
      2021   Phase 2   EUCTR2020-004937-19-ES   China;Germany;Hungary;Israel;Poland;Spain;Switzerland;Taiwan;United Kingdom;
   Novartis Pharma AG
      2021   Phase 2   EUCTR2020-004937-19-HU   China;Germany;Hungary;Israel;Poland;Spain;Switzerland;Taiwan;United Kingdom;
      2021   Phase 2   EUCTR2020-004937-19-DE   China;Germany;Hungary;Israel;Poland;Spain;Switzerland;Taiwan;United Kingdom;
   Novartis Pharmaceuticals
      2021   Phase 2   NCT04988087   China;Germany;Hungary;Spain;United Kingdom;
MabThera
   Royal Brompton and Harefield NHS Foundation Trust
      2013   -   EUCTR2012-003633-42-GB   United Kingdom;
Rituximab
   Royal Brompton & Harefield NHS Foundation Trust
      2014   Phase 2/Phase 3   NCT01862926   United Kingdom;
   Royal Brompton and Harefield NHS Foundation Trust
      2013   -   EUCTR2012-003633-42-GB   United Kingdom;
   Yokohama City University Hospital Department of Pediatrics
      2015   -   JPRN-UMIN000018376   Japan;
Yellow Fever vaccine (17D)
   University of Sao Paulo General Hospital
      2018   -   NCT03430388   Brazil;